BioSpace News Archive

Business

Med Alliance Announces Strategic Agreement With Kaneka Corporation

The agreement involves technical collaboration, product licensing, manufacturing and distribution for the Med Alliance sirolimus Drug-Coated Balloon in Japan for the treatment of coronary arteries.

January 2, 2018
·
1 min read
Compugen Announces Presentations at Three Upcoming Cancer Immunotherapy Conferences

The poster titled “PVRIG Expression is Associated with T Cell Exhaustion and Synergizes with TIGIT to Inhibit Anti-Tumor Responses” will be presented on Thursday, January 18, 2018 at the Keystone Symposia Conference

January 2, 2018
·
4 min read
Drug Development

Progenics Pharmaceuticals Completes Enrollment in Phase III Study of PSMA-Targeted Imaging Agent 1404

Top-line data is expected in 3Q2018.

January 2, 2018
·
5 min read
Business

Promore Pharma Adjusts Plans for PXL01 in North America

Promore Pharma today announced that it will continue and widen its efforts to seek funding for a Phase III clinical trial on PXL01 in North America.

January 2, 2018
·
4 min read
Business

Radius Health Welcomes Elhan Webb as Head of Investor Relations and External Communications

Ms. Webb is a CFA charterholder and joins Radius from Genfit Corporation where she was Vice President and Head of Investor Relations.

January 2, 2018
·
1 min read
Business

OncoResponse Expands Scientific Leadership With the Addition of Dr. Anil Singhal as CSO and Dr. Kamal D. Puri as VP, R&D

OncoResponse today announced it has expanded its scientific leadership through the additions of Anil Singhal, Ph.D., and Kamal D. Puri, Ph.D., to the management team.

January 2, 2018
·
2 min read
Business

NRGene Strengthens Cooperation With Chinese Academic Leaders

NRGene, the worldwide leader in genomic assembly and analysis, has partnered with leading researchers to make a significant impact on global agricultural research.

January 2, 2018
·
2 min read
Policy

Selecta Biosciences Announces FDA Acceptance of IND Application for LMB-100 and SVP-Rapamycin Combination Therapy

SVP-Rapamycin is Selecta’s proprietary, clinical-stage anti-drug antibody (ADA) prevention and immune tolerance technology.

January 2, 2018
·
7 min read
Policy

Achaogen Announces FDA Acceptance of NDA With Priority Review for Plazomicin

Achaogen also intends to submit an application for marketing authorization in the European Union in 2018.

January 2, 2018
·
6 min read
Drug Development

Achaogen Announces Positive Top-Line Results From First Clinical Trial of Orally-Administered Antibacterial Candidate C-Scape

The Company also announced that C-Scape is an oral combination of ceftibuten, an approved third generation cephalosporin, and clavulanate, an approved beta-lactamase inhibitor.

January 2, 2018
·
7 min read